BRINEURA cerliponase alfa (rch) 150 mg/5 mL solution for injection vial with flushing solution vial Australia - English - Department of Health (Therapeutic Goods Administration)

brineura cerliponase alfa (rch) 150 mg/5 ml solution for injection vial with flushing solution vial

biomarin pharmaceutical australia pty ltd - cerliponase alfa, quantity: 30 mg/ml - injection, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; sodium chloride; potassium chloride; magnesium chloride hexahydrate; calcium chloride dihydrate; water for injections; monobasic sodium phosphate monohydrate - brineura is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (cln2) disease, also known as tripeptidyl peptidase 1 (tpp1) deficiency.

NAGLAZYME galsulfase-rch 5mg/5mL concentrated solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

naglazyme galsulfase-rch 5mg/5ml concentrated solution for injection vial

biomarin pharmaceutical australia pty ltd - galsulfase, quantity: 5 mg - injection, concentrated - excipient ingredients: monobasic sodium phosphate monohydrate; water for injections; dibasic sodium phosphate heptahydrate; polysorbate 80; sodium chloride - for the long-term enzyme replacement therapy in patients with mucopolysaccharidosis vi (mps vi - n acetylgalactosamine 4-sulfatase deficiency)

VIMIZIM elosulfase alfa (rch) 1 mg/mL concentrated solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

vimizim elosulfase alfa (rch) 1 mg/ml concentrated solution for injection vial

biomarin pharmaceutical australia pty ltd - elosulfase alfa, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: arginine hydrochloride; monobasic sodium phosphate monohydrate; sodium acetate trihydrate; water for injections; polysorbate 20; sorbitol - vimizim is indicated for the treatment of mucopolysaccharidosis type iva (mps iva; morquio a syndrome).

KUVAN sapropterin dihydrochloride 100 mg soluble tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

kuvan sapropterin dihydrochloride 100 mg soluble tablet bottle

biomarin pharmaceutical australia pty ltd - sapropterin dihydrochloride, quantity: 100 mg - tablet, soluble - excipient ingredients: sodium stearylfumarate; calcium hydrogen phosphate; mannitol; crospovidone; ascorbic acid; riboflavin - kuvan is indicated for the treatment of hyperphenylalaninemia (hpa) in sapropterin-responsive adult and paediatric patients with phenylketonuria (pku) or tetrahydrobiopterin (bh4) deficiency (see section 4.2 dose and method of administration for definition of sapropterin responsiveness)

KUVAN sapropterin dihydrochloride 500 mg oral powder sachet Australia - English - Department of Health (Therapeutic Goods Administration)

kuvan sapropterin dihydrochloride 500 mg oral powder sachet

biomarin pharmaceutical australia pty ltd - sapropterin dihydrochloride, quantity: 500 mg - powder, oral - excipient ingredients: mannitol; potassium citrate; sucralose; ascorbic acid - kuvan is indicated for the treatment of hyperphenylalaninemia (hpa) in sapropterin-responsive adult and paediatric patients with phenylketonuria (pku) or tetrahydrobiopterin (bh4) deficiency (see section 4.2 dose and method of administration for definition of sapropterin responsiveness)

KUVAN sapropterin dihydrochloride 100 mg oral powder sachet Australia - English - Department of Health (Therapeutic Goods Administration)

kuvan sapropterin dihydrochloride 100 mg oral powder sachet

biomarin pharmaceutical australia pty ltd - sapropterin dihydrochloride, quantity: 100 mg - powder, oral - excipient ingredients: mannitol; potassium citrate; sucralose; ascorbic acid - kuvan is indicated for the treatment of hyperphenylalaninemia (hpa) in sapropterin-responsive adult and paediatric patients with phenylketonuria (pku) or tetrahydrobiopterin (bh4) deficiency (see section 4.2 dose and method of administration for definition of sapropterin responsiveness)

VOXZOGO vosoritide 1.2 mg powder for injection vial and diluent pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

voxzogo vosoritide 1.2 mg powder for injection vial and diluent pre-filled syringe

biomarin pharmaceutical australia pty ltd - vosoritide, quantity: 1.2 mg - injection, powder for - excipient ingredients: citric acid monohydrate; mannitol; methionine; polysorbate 80; sodium citrate dihydrate; trehalose dihydrate - voxzogo is indicated for the treatment of achondroplasia in paediatric patients whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

VOXZOGO vosoritide 0.56 mg powder for injection vial and diluent pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

voxzogo vosoritide 0.56 mg powder for injection vial and diluent pre-filled syringe

biomarin pharmaceutical australia pty ltd - vosoritide, quantity: 0.56 mg - injection, powder for - excipient ingredients: mannitol; sodium citrate dihydrate; citric acid monohydrate; polysorbate 80; trehalose dihydrate; methionine - voxzogo is indicated for the treatment of achondroplasia in paediatric patients whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

VOXZOGO vosoritide 0.4 mg powder for injection vial and diluent pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

voxzogo vosoritide 0.4 mg powder for injection vial and diluent pre-filled syringe

biomarin pharmaceutical australia pty ltd - vosoritide, quantity: 0.4 mg - injection, powder for - excipient ingredients: citric acid monohydrate; mannitol; polysorbate 80; methionine; trehalose dihydrate; sodium citrate dihydrate - voxzogo is indicated for the treatment of achondroplasia in paediatric patients whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

PALYNZIQ pegvaliase 20 mg/mL solution for injection pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

palynziq pegvaliase 20 mg/ml solution for injection pre-filled syringe

biomarin pharmaceutical australia pty ltd - pegvaliase, quantity: 20 mg - injection, solution - excipient ingredients: sodium chloride; trometamol; water for injections; trometamol hydrochloride; cinnamic acid - palynziq is indicated for the treatment of patients with phenylketonuria (pku) aged 16 years and older who have inadequate blood phenylalanine control despite prior management with available treatment options.